Table 3.

Clinical trials that used TDF and/or FTC/TDF as PrEP for HIV prevention

Clinical Trial	Population	Design	Relative reduction in HIV incidence in intention-to-treat analysis
Partners PrEP	4,747 heterosexual men and women with known HIV- infected partners (serodiscordant couples)	1:1:1 randomization to daily TDF, FTC/TDF or placebo	TDF: 67% (95% CI: 44% to 81%; p < 0.0001) FTC/TDF: 75% (95% CI: 5% to 87%; p < 0.0001)
TDF2	1,219 heterosexual men and women	1:1 randomization to daily oral FTC/TDF or placebo	FTC/TDF: 63% (95 % CI: 22% to 83%; p = 0.01)
iPrEx	2,499 MSM and transgender women	1:1 randomization to daily oral FTC/TDF or placebo	FTC/TDF: 44% (95% I: 15% to 63%; p = 0.005)
Fem-PrEP	2120 women	1:1 randomization to daily oral FTC/TDF or placebo	FTC/TDF: 6% (p = 0.8). No statistically significant reduction in HIV incidence
VOICE	3,019 women (plus 2010 women receiving tenofovir or placebo gel)	1:1:1 randomization to daily oral TDF, FTC/TDF or placebo	TDF: -49% (p = 0.07) FTC/TDF: -4% (p > 0.2) No statistically significant reduction in HIV incidence
Bagkok Tenofovir Study	2,413 injection drug users	1:1 randomization to daily oral TDF or placebo	TDF: 48.9% (95% CI 9.6% to 72.2 %; p = 0.01)